Drugs / UCART123v1.2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03190278 | Jun 2017 → Dec 2024 overdue | acute myeloid leukemia | Cellectis S.A. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCART123v1.2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03190278 ↗ |
| Modality | Cell therapy | “Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor” NCT03190278 ↗ |